Gensenta İlaç

Mustafa Nevzat İlaç, which had served public health for nearly a century, was acquired by the pharmaceutical company Amgen in 2012. Having adopted the name Gensenta in 2020 and facilitated patients' access to medicine through its efforts to deliver new and comprehensive solutions to more patients across a broader geography, Gensenta has, as of November 2022, continued its operations as one of the companies of the Eczacıbaşı Group.

With its expert workforce of 600 employees and its modern facilities, Gensenta is one of Türkiye's leading manufacturers of both finished pharmaceutical products and active pharmaceutical ingredients. At the Gensenta Active Ingredient Production Facilities, penicillin-group active pharmaceutical ingredients, Etodolac and other active pharmaceutical ingredients are manufactured in four separate, mutually independent production units. Gensenta, which operates the only penicillin production facility in Türkiye, successfully passed FDA approval in 2006 with both its active ingredient and finished product facilities, thereby becoming the first Turkish pharmaceutical manufacturer to obtain FDA approval for a finished product.

In its facilities, which hold ISO 14001, ISO 45001 and ISO 50001 management system certifications and operate in compliance with the world-class rules of "current Good Manufacturing Practices (cGMP)" and "current Good Laboratory Practices (cGLP)", Gensenta places the medicines it produces — along with new and comprehensive solutions — at the service of human health both in Türkiye and in many countries abroad, drawing on continuous training, accumulated expertise and modern technology.